艾美捷抗人干擾素α單抗MT2背景：

干擾素-alpha（IFN-alpha）是I型干擾素，存在13種亞型：IFN-alpha1，2，4，5，6，7與其他亞型一樣，干擾素-alpha2（IFN-alpha2）主要由病毒產(chǎn)生。在感知到病毒DNA或RNA等危險信號的存在后感染細胞。因此IFN-alpha2與其受體的結(jié)合引發(fā)抗病毒反應(yīng)，但也顯示出抗腫瘤作用。作為個被發(fā)現(xiàn)，IFN-alpha2是研究J為廣泛的亞型，它已被用作細胞因子治療與丙型肝炎病毒感染。

艾美捷抗人干擾素α單抗MT2基本參數(shù)：

英文名稱：Anti-human IFN-alpha mAb (MT2), biotin

編號：3423-6-1000

規(guī)格：1mg

應(yīng)用類型：ELISpot, ELISA

免疫原：天然和重組人IFN-a亞型2a, 2b, 2c

來源宿主：小鼠

反應(yīng)性：人

保存建議：建議2-8°C保存，有效期為18個月。

艾美捷抗人干擾素α單抗MT2參考文獻：

Bijak, M., et al. (2017). Flavonolignans Inhibit IL1-β-Induced Cross-Talk between Blood Platelets and Leukocytes. Nutrients.

Chan, L. J., et al. (2017). An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration. Biomacromolecules.

Hochmann, S., et al. (2018). Evaluation of modified Interferon alpha mRNA constructs for the treatment of non-melanoma skin cancer. Sci Rep.

Ingelsson, B., et al. (2018). Lymphocytes eject interferogenic mitochondrial DNA webs in response to CpG and non-CpG oligodeoxynucleotides of class C. Proceedings of the National Academy of Sciences of the United States of America.

Yadav, P., et al. (2018). Distribution of therapeutic proteins into thoracic lymph after intravenous administration is protein size-dependent and primarily occurs within the liver and mesentery. J Control Release.